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The main clinical features of two siblings from a consanguineous marriage were progressive myoclonic
epilepsy without intellectual impairment and a nephrotic syndrome with a strong accumulation of C1q in
capillary loops and mesangium of kidney. The biochemical analysis of one of the patients revealed a
normal b-glucocerebrosidase activity in leukocytes, but a severe enzymatic deficiency in cultured skin fibro-
blasts. This deficiency suggested a defect in the intracellular sorting pathway of this enzyme. The sequence
analysis of the gene encoding LIMP-2 (SCARB2), the sorting receptor for b-glucocerebrosidase, confirmed
this hypothesis. A homozygous nonsense mutation in codon 178 of SCARB2 was found in the patient,
whereas her healthy parents were heterozygous for the mutation. Besides lacking immunodetectable
LIMP-2, patient fibroblasts also had decreased amounts of b-glucocerebrosidase, which was mainly located
in the endoplasmic reticulum, as assessed by its sensitivity to Endo H. This is the first report of a mutation in
the SCARB2 gene associated with a human disease, which, contrary to earlier proposals, shares no features
with Charcot–Marie–Tooth disease both at the clinical and neurophysiological levels.
INTRODUCTION
Lysosomal integral membrane protein type 2 (LIMP-2), the
product of the SCARB2 gene (1) (MIM 602257), is a
member of the CD36 superfamily of proteins (2,3). LIMP-2
is a ubiquitously expressed 478 amino acid transmembrane
protein (4), mainly found in lysosomes and late endosomes
(5). Topologically, LIMP-2 has both termini exposed to the
cytosol, two transmembrane domains and a 400-residue long
luminal domain (6). The targeting and localization of
LIMP-2 to late endosomes and lysosomes are mediated by a
di-leucine motif present in its C-terminal cytosolic tail (7,8).
Several independent observations suggesting that LIMP-2 is
required for the biogenesis and maintenance of the lysosomal/
endosomal system have been reported over the past years
(9,10). A major advancement, however, was made recently by
Reczek et al. (11) in a work, showing that LIMP-2 is the
mannose-6-phosphate independent trafficking receptor for
b-glucocerebrosidase (b-GCase), a lysosomal enzyme that is
deficient in most cases of Gaucher disease (GD) (reviewed
in 12). The LIMP-2/b-GCase interaction involves amino acid
residues 150–167 of LIMP-2 and is much stronger at neutral
than at the acidic pH typically found in lysosomes (11). This
and other observations led the authors to propose that LIMP-2
binds b-GCase in the endoplasmic reticulum (ER) and escorts
the enzyme to the late endosomes/lysosomes, where the
acidic pH dissociates the receptor–cargo protein complex (11).
The importance of the LIMP-2-mediated protein sorting
pathway is illustrated by the phenotype of LIMP-2 knockout
(KO) mice. The absence of this protein in mice causes
urinary and neurological alterations (11), associated with
impaired vesicular trafficking and distribution of apically
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expressed proteins (13). An intriguing property of these mice,
however, regards the tissue-specific differences observed both
at the level of b-GCase activity and accumulation of glucosyl-
ceramide, the substrate of b-GCase (11). Indeed, increased
levels of glucosylceramide were found in the liver and lungs
of these mice, whereas no accumulation was detected in
spleen, kidney or brain. Regarding b-GCase activity, a
5-fold decrease was detected in liver extracts of LIMP-2 KO
mice (20% of the wild-type level), whereas in brain, this
factor was only 1.7. The reason for these differences is pre-
sently unknown, although some hypotheses have been for-
warded (11).
Given the important role of LIMP-2 in the lysosomal sorting
of b-GCase in mice and in cultured human-derived cell lines
(11), the possibility that mutations in the SCARB2 gene are
associated with disease in humans seems highly likely. In
fact, a molecular screening for LIMP-2 mutations in patients
with Charcot–Marie–Tooth disease has been initiated (9).
However, a disease-associated LIMP-2 mutation has not
been described thus far.
In this work, we describe a deficiency in LIMP-2 resulting
from a nonsense mutation in the SCARB2 gene. When in a
homozygous state, the mutation was associated with progress-
ive myoclonic epilepsy without intellectual impairment and a
nephrotic syndrome with strong accumulation of C1q in capil-
lary loops of the kidney.
RESULTS
Clinical phenotype of the patients
Two sisters from a northern Portuguese family (patients 1 and
2, respectively) presenting progressive myoclonic epilepsy and
nephrotic syndrome were studied. The patients had an older
healthy sister. Their parents were first-degree cousins with a
normal neurological examination. Patient 1 started to have
myoclonic jerks during active movements of the upper limbs
at the age of 15. Symptoms progressed insidiously in intensity,
reaching the lower limbs and the trunk later on, developing
instability of the gait. When she was 18, she exhibited
slowed horizontal saccadic eye movements. A proteinuria of
1 g/24 h was detected at this time. At the age of 20, she was
totally dependent, unable to write, to eat alone or to walk,
and she had a blurred speech with swallowing difficulties.
One year later, she had edemas in both lower limbs and ana-
sarca with bilateral pleural effusions. Nephrotic syndrome,
normocytic normochromic anemia and thrombocytopenia
were diagnosed. At this time, renal and bone marrow biopsies
were performed. The histological analysis of the medullar
zone in renal material revealed extensive tubular alterations
with isometric vacuolization in distal and collecting tubules
and the presence of granular material in cortical tubules
without inflammatory infiltration deposits. No ‘Gaucher
cells’ were identified. A marked deposition of C1q and IgM
and irregular moderate deposits of C3 in capillary loops and
mesangium were observed by immunofluorescence. Bone
marrow biopsy was normal. Again, no ‘Gaucher cells’ were
found. She died at the age of 23 with a methicilin-resistant
Staphylococcus aureus and Candida albicans septicemia
with multiorgan failure.
Patient 2 developed basically the same type of symptoms as
her sister at the age of 17 with only minor differences. When
she was 20, she had slowed horizontal saccadic eye
movements. At the age of 21, she presented nephrotic syn-
drome, and 1 year later, she was totally dependent. At the
age of 23, she had a normocytic normochromic anemia and
hypoalbuminemia, but no thrombocytopenia. Like her sister,
she had no hepatosplenomegaly and no intellectual impair-
ment. She died at the age of 26 with a fulminant pneumonia
due to an unidentified agent.
b-GCase activity is deficient in skin fibroblasts
but not in leukocytes of patient 2
As stated earlier, the two patients described in this study pre-
sented a progressive myoclonic epilepsy, a syndrome shared
by a group of rare and heterogeneous disorders, such as
Niemann–Pick disease type C (MIM #257220) (14,15) and
neuronopathic forms of GD (MIM #231000) (reviewed in
16). Owing to their neurological features, namely, the myoclo-
nic jerks and ocular movement abnormalities, they were clini-
cally suspected of Niemann–Pick disease type C, a lysosomal
storage disease characterized by lysosomal/late endosomal
accumulation of endocytosed unesterified cholesterol
(reviewed in 17). However, no cholesterol accumulation, as
assessed by filipin staining (18), could be detected in cultured
skin fibroblasts from patient 2 (unpublished data), which
excluded this disease as the cause of the symptoms.
The existence of an atypical neurological type III GD in
these patients was still considered. In order to test this possi-
bility, we determined the activities of b-GCase and several
other enzymes in skin fibroblasts, leukocytes and plasma
from patient 2, her parents and her healthy sister. As shown
in Table 1, patient 2 fibroblasts presented a very low activity
of b-GCase (10% of the controls). The measured activity is,
in fact, close to the values observed in GD patients’ fibro-
blasts. Strikingly, however, in contrast to GD patients,
b-GCase activity in patient 2 leukocytes was normal. The
activity of chitothriosidase, an enzyme secreted by activated
macrophages and a surrogate marker of GD (19), was also
normal in patient 2 plasma. All the other enzymatic activities
analyzed were comparable with the control values (Table 1).
Finally, no mutations were found in the b-GCase gene of
patient 2 by sequencing of exonic regions and intronic bound-
aries (unpublished data). Thus, no evidence for the existence
of GD in these patients could be found at the biochemical or
genetic level.
A homozygous nonsense mutation in the SCARB2
gene in patient 2
Newly synthesized b-GCase is sorted from the ER to the
lysosome by LIMP-2 (11). However, for reasons that are still
unclear, the absence of LIMP-2 in mice does not result in
the same degree of b-GCase deficiency in all tissues (11).
Considering the b-GCase activity values described earlier for
fibroblasts and leukocytes from patient 2, we decided to
analyze the LIMP-2 gene (SCARB2). As shown in Figure 1,
sequencing of exonic regions of the LIMP-2 gene revealed a
homozygous G-to-A substitution in exon 4 (c.533G.A) in
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patient 2. This mutation results in the substitution of a TGG
coding for W178 by a premature stop codon. The presence of
this mutation in other members of the patient 2 family was
studied by restriction enzyme analysis (the G-to-A transition
creates a cleavage site for FspBI). As shown in Figure 2, both
parents were found to be heterozygous for the c.533G.A
mutation. No mutation was found in her healthy sister.
b-GCase in LIMP-2-deficient fibroblasts is decreased
and is sensitive to Endo H digestion
As expected from the nonsense mutation found in the
SCARB2 gene, no LIMP-2 could be detected in total protein
extracts from patient 2 skin fibroblasts (Fig. 3, upper panel),
whereas a normal amount of LAMP-2, a lysosomal-associated
membrane protein (reviewed in 6), was observed (Fig. 3,
middle panel). Interestingly, the steady-state levels of
b-GCase in patient 2 fibroblasts were significantly lower
than the ones observed in control cells. Moreover, in patient
2 cells, only one protein band was detected with the
anti-b-GCase antibody, whereas in control cells, several
bands corresponding to different glycosylated forms of
b-GCase (20) were observed (Fig. 3, lower panel).
The abnormal glycosylation pattern observed for b-GCase
in patient 2 fibroblasts is probably the result of intracellular
missorting due to the absence of LIMP-2. In order to corrobo-
rate this interpretation, protein extracts from patient 2 and
control fibroblasts were subjected to Endo H digestion (21).
As shown in Figure 4, the vast majority of b-GCase in
normal cells is Endo-H-resistant, implying that most of the
protein synthesized in the ER crossed the mid-Golgi and
acquired an N-glycan complex structure. In contrast, in
LIMP-2-deficient fibroblasts, b-GCase is Endo-H-sensitive,
suggesting that its high mannose moieties were not yet pro-
cessed into complex N-glycans (Fig. 4, upper panel). Thus,
the absence of LIMP-2 in patient 2 fibroblasts leads to a
depletion of post-Golgi forms of b-GCase, an observation
that is in perfect agreement with the recently described role
of LIMP-2 (11).
Table 1. Enzymatic activities of lysosomal enzymes in fibroblasts, leukocytes and plasma
Enzymes Patient Parents Control (n ¼ 100) GD patients (n ¼ 25)
Father Mother
Fibroblasts (nmol/h/mg protein) b-GCase 33.9 201 171 301.71 + 89.42 11.2 + 6.8
Hex T 7457 7583 7932 5729 + 1702 7291 + 3378
Hex A 233 795 832 542 + 106 448 + 218
b-gal 242 689 836 758 + 225 496 + 215
Leukocytes (nmol/h/mg protein) b-GCase 7 10 12 10.54 + 2.34 1.1 + 0.8
Hex T 1759 1995 2285 1379 + 442 1978 + 652
Hex A 169 394 411 207 + 56 197 + 57
b-gal 178 245 333 219 + 63 211 + 73
Plasma (nmol/h/ml) Chito 26.4 35 34 39 + 29 11610 + 9898
Ac Phosp 529 290 347 229 + 128 3093 + 1891
Hex T 608 858 898 786 + 222 1900 + 951
Hex A 93 60 58 63 + 15 215 + 136
b-gal 9.5 3 3 3 + 1 13 + 8
Enzymatic activities of the lysosomal enzymes were determined in samples from patient 2, her parents, controls and GD patients as described in
Materials and methods. Values correspond to a representative determination in the case of the patients and parents and to the mean+SD for controls and
GD (n, number of individuals whose enzymatic activity was determined).
Figure 1. The sequence analysis of the SCARB2 gene revealed homozygosity
for c.533G.A mutation. Direct sequencing of exon 4 of the patient and a
control revealed the homozygous G-to-A substitution at position 533, resulting
in a tryptophan-to-stop codon change. Arrow indicates the G-to-A mutation in
the patient.
Figure 2. Detection of the c.533G.A mutation by restriction analysis. G-to-A
transition at position 533 creates a cleavage site for FspBI. The mutant 170 bp
fragment is digested giving two fragments of 137 and 33 bp, whereas wild-
type (wt) fragments remain uncleaved. Arrows indicate the 170 and 137 bp
fragments.
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DISCUSSION
In this work, we describe for the first time a deficiency in
human LIMP-2, the sorting receptor for b-GCase. A bio-
chemical and molecular characterization of one of two
sisters presenting identical neurological and renal symptoms
revealed the existence of a homozygous nonsense mutation
in codon 178 of the LIMP-2 gene. In principle, such a
mutation could still allow the synthesis of a truncated
protein comprising amino acid residues 1–177 of LIMP-2, a
possibility that could not be addressed in this work (the
anti-LIMP-2 antibody used here recognizes the C-terminus
of the protein). However, even if we assume that such trun-
cated protein is indeed produced, stable and capable of inter-
acting with b-GCase, the fact that it lacks the C-terminal
late endosomal/lysosomal targeting information suggests that
it would not be functional in sorting its cargo protein(s). As
shown by Vega et al. (22), the deletion of just 47 amino
acid residues from the C-terminus of LIMP-2 renders the trun-
cated protein unable to reach the late endosomal/lysosomal
compartments and results in an ER and plasma membrane
localization. More significantly, as far as the detection limits
of a western blotting analysis allow us to say, no fully
matured Endo-H-resistant b-GCase could be found in skin
fibroblasts from the patient, an observation strongly suggesting
that the majority of the enzyme present in these cells never
reaches the Golgi apparatus. Thus, at least in the ex vivo
studies, the effects of the c.533G.A mutation seem to be
quite similar to those observed in mice cells completely
lacking LIMP-2 (11).
One intriguing aspect of the data presented here regards the
juvenile onset of symptoms in the patients. Apparently, the
absence of a fully functional LIMP-2 protein is compatible
with a normal life for more than a decade. This is in sharp con-
trast to the situation observed in GD, in which in the most
severe cases, early infantile and even neonatal onsets have
been described (23). Therefore, at the phenotypic level, it
seems that the lack of the sorting receptor LIMP-2 has less
severe consequences than lack of the cargo it sorts, a con-
clusion also supported by the phenotypes of the LIMP-2 and
b-GCase KO mice (11,24). There may be several explanations
for this apparent paradox. It is possible that a residual amount
of b-GCase reaches the lysosome even in the absence of
LIMP-2. Small amounts of b-GCase may be sorted to the lyso-
some by a direct mechanism, by an as-yet unidentified protein,
or indirectly, by endocytosis of secreted b-GCase. Alterna-
tively, it is possible that the relatively large pool of b-GCase
detected in pre-Golgi compartments in both normal and
LIMP-2-deficient cells (11,21; see also Fig. 4) is more import-
ant for the cell lipid homeostasis than presently assumed.
Clearly, further work is necessary to clarify these questions.
It is noteworthy that the clinical phenotype of the patients
described here does not correlate with the phenotype of
LIMP-2 KO mice, despite the neurological and renal involve-
ment observed in both. In LIMP-2 KO mice, neurological
alterations translate into deafness and peripheral neuropathy,
whereas no such symptoms were observed in the patients.
Instead, progressive myoclonic epilepsy without intellectual
impairment was the most important neurological feature. At
the renal level, LIMP-2 KO mice present an obstruction of
the ureteropelvic junction, whereas no urinary tract obstruc-
tion was observed in the patients. The patients developed a
C1q nephropathy, a relatively rare type of glomerulonephritis
with a still unknown pathogenesis mechanism (25).
The absence of a correlation between the LIMP-2 KO mice
phenotype and the clinical phenotype of the patients described
here has implications for future genetic screening of LIMP-2
deficiencies. For instance, based on the phenotype of the
LIMP-2 KO mice, it was previously suggested that some
patients with Charcot–Marie–Tooth, a sensorineural periph-
eral polyneuropathy, might have mutations in the LIMP-2
gene (9). In the light of our findings, this possibility seems
now improbable.
While this manuscript was under revision, Berkovic et al.
(26) described LIMP-2 mutations in three patients with
action myoclonus-renal failure syndrome.
Figure 3. Western blotting analysis of LIMP-2, LAMP-2 and b-GCase in
fibroblasts extracts. Fibroblast homogenates with the same amount of
protein (80 mg) from the patient and a healthy control were immunoblotted
for LIMP-2 (upper panel), LAMP-2 (middle panel) and b-Gcase (lower panel).
Figure 4. ER retention of b-GCase in LIMP-2-deficient fibroblasts. Fibroblast
lysates with the same amount of protein (15 mg) from the patient and a control
were treated with Endo-H (upper panel) and PNGase F (lower panel) and
immunoblotted for b-GCase. Unspecific band occasionally detected by the
antibody.
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MATERIALS AND METHODS
Materials
The monoclonal antibody against human LAMP-2 (H4B4),
developed by August and Hildreth, was obtained from the
Development Hybridoma Bank under the auspices of the
NICHD and maintained by the Department of Biological
Sciences, University of Iowa, Iowa City, IA, USA. The
monoclonal antibody against human b-glucocerebrosidase
(8E4) (27) was kindly provided by Professor Aerts, E.C.
Slater Institute for Biochemical Research, University of
Amsterdam, The Netherlands. The rabbit polyclonal anti-
LIMP-2 antibody was kindly provided by Novus Biologicals,
Littleton, USA.
4-Methylumbelliferyl (MU)-b-D-glucopyranoside, 4-MU-
phosphate-free acid and 4-MU-b-D-galactopyranoside were
purchased from Glycosynth; 4-MU-b-N-acetylglucosami-
nide-6-sulfate was purchased from Moscerdam Substrates;
4-MU-N-acetyl-b-D-glucosaminide and 4-MU-b-D-N,N0,N00-
triacetylchitotrioside were purchased from Sigma-Aldrich.
Endo-H and PNGase F were from New England Biolabs.
Restriction enzymes were from Fermentas Life Sciences.
Biological samples
Despite the fact that we described two patients clinically, we
only had access to biological samples of patient 2. Fibroblasts
obtained from skin biopsies were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, 1% penicillin–streptomycin,
100 mg/ml kanamycin sulfate and 2.5 mg/ml fungizone
(Gibco, Invitrogen). Cells were grown at 378C in the presence
of 5% CO2. Plasma and leukocytes were separated from whole
blood, according to standard methods. DNA was extracted
from whole blood with PuregeneTM DNA Isolation Kit
(Gentra Systems).
Enzymatic activity assays
4-MU-based activity assays were performed for the determi-
nation of enzymatic activity of b-GCase, hexosaminidase T
(Hex T), hexosaminidase A (Hex A), b-galactosidase
(b-Gal), in fibroblasts and leukocytes. Chitotriosidase
(Chito), acid phosphatase (Ac Phosp), Hex T, Hex A and
b-Gal enzymatic activities were determined in plasma, as
described previously (28–31).
Molecular analysis
Regions of the SCARB2 gene were amplified and sequenced
using the following primers: SCARB2-exon 3-F: 50-
ATGTTTTTGAACGAGACCAATCTGT-30; SCARB2-exon
3-B: 50-TCCTTTCTTCCAAAATCCAACTTA-30; SCARB2-
exon 4-F: 50-TGCTGTTCTTAATATACCTCTGCTCC-30;
SCARB2-exon 4-B: 50-GGATAAGGGACAAGATTTCAT
CTTT-30; SCARB2-exon 9-F: 50-TTTAATAAATCCTAATG
TTTCCTTTTCACTTC-30; SCARB2-exon 9-B: 50-AACT
GCTGTCCCCTCCATAGAA-30; SCARB2-exon 12-F: 50-G
AACATCTAACTTGTTTTCTCT-30 and SCARB2-exon
12-B: 50-ATGATTTTATAAAGCTTAATGG-30.
SDS–PAGE and western blotting
Fibroblast monolayers at 90% confluence were harvested, washed
three times in phosphate-buffered saline and sonicated at 48C in
SEM buffer (0.25 M sacarose, 20 mM MOPS-KOH, pH 7.2,
1 mM EDTA-NaOH, pH 7.2), supplemented with 2 mg/ml
N-(trans-epoxysuccinyl)-L-leucine 4-guanidinobutylamide.
Lysates were centrifuged at 1000g for 10 min at 48C. Proteins
were quantified by the Bradford technique (32). Samples contain-
ing the same amount of protein were subjected to SDS–PAGE
and electroblotted onto a nitrocellulose membrane (Schlei-
cher&Schuell). Membranes were blocked with 5% skimmed
milk and 0.1% Tween-20 in Tris-buffered saline (TBS) for 1 h
at room temperature and incubated overnight with the primary
antibodies at 48C. Membranes were then washed twice with
0.1% Tween-20 in TBS and incubated with the appropriate sec-
ondary antibodies for 1 h at room temperature. After washing,
detection was performed using alkaline-phosphatase substrates.
Endo H and PNGase treatment
Samples of fibroblast lysates, containing 15 mg of total
protein, were treated overnight with Endo-H or PNGase F,
according to the manufacturer’s instruction (New England
BioLabs).
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